Association of biliverdin reductase A with mild cognitive impairment in type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300078678

Enrollment

Unknown

Registered

2023-12-14

Start date

2023-12-14

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

MCI (Mild Cognitive Impairment) group:None

Normal cognitive function group:None

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: A total of 40 patients with T2DM were recruited from the Department of Endocrinology, Affiliated Hospital of Xuzhou Medical University. According to the 2020 Chinese Guidelines for the Prevention and Treatment of Diabetes, diabetes can be diagnosed if at least one of the following conditions is met: 1) Diabetes symptoms (typical symptoms are polydipsia, polyphagia, polyphagia, polyuria and unexplained weight loss) plus random blood glucose = 11.1 mmol/L; 2) fasting blood glucose (FPG) level = 7.0 mmol/L; 3) oral glucose tolerance test (OGTT), plasma glucose (2hPG) level = 11.1 mmol/L 2 h after glucose loading, and patients without typical diabetes symptoms should be rechecked on another day for confirmation. MCI (Mild Cognitive Impairment) group: The diagnostic criteria for MCI in all patients were based on the diagnostic criteria of the 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment. Normal cognitive function group: patients who meet the diagnostic criteria for type 2 diabetes mellitus and do not have MCI

Exclusion criteria

Exclusion criteria: Exclusion Criteria: (1) Patients with type 1 diabetes. (2) Acute diabetic complications within the past 3 months. (3) Acute inflammation, autoimmune diseases, cardiac, respiratory, liver or kidney failure. (4) Patients with acute stroke, myocardial infarction or severe neurological deficit; (5) Other specific diseases that may be related to cognitive impairment, such as brain injury, epilepsy, malignancy, anxiety, depression, hypothyroidism, hyperthyroidism, carbon monoxide poisoning, schizophrenia, anxiety or depression. (6) History of hearing/visual impairment or psychological impairment. (7) Any incomplete data set.

Design outcomes

Primary

Measure	Time frame
Biliverdin reductase A ;	—

Countries

China

Contacts

Public ContactYing Changjiang

Affiliated Hospital of Xuzhou Medical University

ycj321651@163.com+86 139 1488 8751

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026